That's kind of how it feels to realize late in your career that you're behind in saving for retirement. You know that if you ...

The Food and Drug Administration is meeting next month to consider easing restrictions on several peptides, a group of ...

The truth is much simpler. Compound interest is one of the easiest concepts to understand once someone explains it clearly. More importantly, it is one of the most important ideas in personal finance, ...

LONDON/NEW YORK, May 21 (Reuters) - Lower prices for weight-loss pills from Novo Nordisk (NOVOb.CO), opens new tab and Eli Lilly (LLY.N), opens new tab are prompting patients to switch from compounded ...

The Food and Drug Administration on Thursday proposed excluding Novo Nordisk and Eli Lilly’s ‌weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

A recent op-ed in the Washington Post describes the story of an author who decided he wanted to lose weight. Although he was healthy, he heard from friends how easy and effective GLP-1 medications ...

As GLP-1 medications grow in popularity not just for treating diabetes but also for weight loss, some people are turning to alternatives that health experts warn may carry risks. Amelia Baker, a ...

Caroline Banton has 6+ years of experience as a writer of business and finance articles. She also writes biographies for Story Terrace. Amy is an ACA and the CEO and founder of OnPoint Learning, a ...

Drugmaker Eli Lilly says some copycat versions of its GLP-1 medications pose unique safety concerns — here’s what you need to know. A new study funded by Eli Lilly found that mixing compounded ...

Eli Lilly stressed that tirzepatide has never been studied in combination with vitamin B12 and warned that the compounders making these products aren’t required to monitor and report potential ...

New warning letters follow an FDA crackdown on GLP-1 drug compounding that intensified last month with explicit pledges of "swift action." (iStock / Getty Images Plus) The FDA is taking no prisoners ...